Literature DB >> 20376582

Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.

Li Wei1, HongLi Zuo, XueDong Sun, TieQiang Liu, Mei Guo, GuangXian Liu, QiYun Sun, JianHui Qiao, DanHong Wang, ChangLin Yu, KaiXun Hu, Zheng Dong, HuiSheng Ai.   

Abstract

Clinical studies have shown that NST has better therapeutic results with chronic myelogenous leukemia (CML) than acute leukemia (AL), but whether the generation of graft-versus-leukemia (GVL) effects is different between AL and CML patients early after NST has not yet been studied, so we used a pentamer-staining technique in combination with ICCS to detect WT1(+)CD8(+)CTL/WT1(+)Tc1 and WT1(+)Th1 cells in these two groups of patients. Results showed that the emergence time of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 cells after NST in AL patients was similar to that in CML patients (P = 0.58), while the emergence time of WT1(+)Th1 cells after NST in AL patients was shorter than in CML patients (P = 0.047). Furthermore, the peak proportions of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 (P > 0.05) and WT1(+)Th1 (P > 0.05) cells were similar between AL and CML patients, and the increased rates (P > 0.05) and elevated levels (P > 0.05) of WT1-specific T cells were not statistically different between the groups after G-CSF mobilized donor mononuclear cell infusion. In addition, the reconstruction of lymphocyte subsets (P > 0.05) and CD4/8 ratios (P > 0.05) in AL patients were not statistically different from those in CML patients within 180 days after NST. These results suggested that WT1 maybe induces similar GVL effects in both AL and CML patients early after NST.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376582     DOI: 10.1007/s12185-010-0551-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  [The Antitumor Activity of G-CSF-Mobilized Peripheral Blood Mononuclear Cells Activated by IL-2 Alone or in Combination with IL-12]

Authors:  Wan-Jun Sun; Zi-Kuan Guo; Hui-Sheng Ai
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2001-12

2.  Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.

Authors:  D H Fowler; J Breglio; G Nagel; C Hirose; R E Gress
Journal:  Biol Blood Marrow Transplant       Date:  1996-10       Impact factor: 5.742

Review 3.  Donor leukocyte transfusions for leukemic relapse.

Authors:  F van Rhee; H J Kolb
Journal:  Curr Opin Hematol       Date:  1995-11       Impact factor: 3.284

4.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

5.  Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.

Authors:  Anne Marie Asemissen; Ulrich Keilholz; Stefan Tenzer; Margret Müller; Steffen Walter; Stefan Stevanovic; Hansjörg Schild; Anne Letsch; Eckhard Thiel; Hans-Georg Rammensee; Carmen Scheibenbogen
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

6.  Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han
Journal:  Haematologica       Date:  2007-03       Impact factor: 9.941

7.  Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.

Authors:  Ming-Huang Chen; Tzeon-Jye Chiou; Peng-Chan Lin; Jyh-Pyng Gau; Hui-Chi Hsu; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

Authors:  A S Michallet; F Nicolini; S Fürst; Q H Le; V Dubois; S Hayette; J P Bourgeot; J P Tremisi; X Thomas; L Gebuhrer; M Michallet
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

9.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

10.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.